mTOR Signaling and Cancer Progression

mTOR exists in two functionally distinct multiprotein complexes: mTORC1 and mTORC2. mTORC1 primarily regulates cell growth and proliferation by upregulating protein and lipid biosynthesis while downregulating autophagy. mTORC2 has distinct functions in the broader mTOR signaling network. Both complexes respond to environmental cues like nutrient availability and growth factors to control fundamental cellular processes.

Growth factors like insulin bind to receptor tyrosine kinases, activating PI3K. Active PI3K generates PIP3, enabling PDK1 to phosphorylate and activate AKT. Active AKT then phosphorylates and inhibits the TSC complex, which normally keeps RHEB inactive. With TSC inhibited, RHEB remains in its active GTP-bound state and activates mTORC1, promoting cell growth and proliferation.

The TSC complex is a growth-suppressing protein with GTPase-activating activity. In its active state, it converts RHEB from an active to inactive state, keeping mTORC1 inactive. When AKT phosphorylates and inactivates the TSC complex, RHEB can remain active and stimulate mTORC1. This mechanism allows cells to control mTORC1 activity in response to growth signals.

Upon activation, mTORC1 upregulates protein synthesis by phosphorylating 4EBP1 and S6K1. S6K1 activation also regulates SREBP, a transcription factor controlling lipid synthesis. Additionally, S6K1 activates CAD, which plays a critical role in de novo pyrimidine synthesis. Through these mechanisms, active mTORC1 supports the biosynthesis of macromolecules needed for cell growth.

Cancer cells exploit the mTOR pathway because mutations in mTOR signaling genes lead to abnormal pathway activation even without appropriate growth signals. This allows tumor cells to evade autophagy and continuously synthesize proteins and lipids to support early tumor progression. Because mTOR controls cell growth and metabolism, its deregulation provides cancer cells with sustained growth advantages independent of normal environmental cues.

Inhibition of mTORC1 increases autophagy, while stimulation of mTORC1 reduces autophagy. In cancer cells, active mTORC1 downregulates autophagy, preventing cells from breaking down their own components. Additionally, mTORC1 facilitates the Warburg effect, shifting glucose metabolism from oxidative phosphorylation to glycolysis, enabling rapid energy generation for tumor cell growth and proliferation.

mTOR responds to various environmental cues including nutrient availability, growth factors, and cellular stress. The presence of insulin or insulin-like growth factors activates the PI3K/AKT/mTOR pathway. In the absence of essential nutrients, cells activate autophagy to supply amino acids and other basic components. This responsive regulation allows normal cells to balance anabolic processes like protein synthesis with catabolic processes like autophagy.